Natural Investments LLC Acquires New Holdings in Colgate-Palmolive (NYSE:CL)

Natural Investments LLC bought a new position in Colgate-Palmolive (NYSE:CL) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 4,667 shares of the company’s stock, valued at approximately $424,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CL. Kohmann Bosshard Financial Services LLC acquired a new stake in Colgate-Palmolive during the 4th quarter worth $26,000. Centricity Wealth Management LLC acquired a new stake in shares of Colgate-Palmolive during the fourth quarter worth about $27,000. Union Bancaire Privee UBP SA bought a new position in shares of Colgate-Palmolive during the 4th quarter valued at about $32,000. Briaud Financial Planning Inc acquired a new position in shares of Colgate-Palmolive in the 4th quarter valued at approximately $32,000. Finally, Bernard Wealth Management Corp. bought a new stake in Colgate-Palmolive during the 4th quarter worth approximately $36,000. 80.41% of the stock is owned by institutional investors.

Colgate-Palmolive Stock Performance

CL opened at $94.05 on Wednesday. The company has a quick ratio of 0.58, a current ratio of 0.92 and a debt-to-equity ratio of 13.40. The stock has a market cap of $76.32 billion, a price-to-earnings ratio of 26.72, a PEG ratio of 4.20 and a beta of 0.40. Colgate-Palmolive has a 12-month low of $85.32 and a 12-month high of $109.30. The business has a 50 day moving average of $89.03 and a 200-day moving average of $94.99.

Colgate-Palmolive (NYSE:CL) last released its quarterly earnings data on Friday, January 31st. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.01. Colgate-Palmolive had a net margin of 14.38% and a return on equity of 477.77%. During the same quarter in the previous year, the business earned $0.87 earnings per share. On average, equities research analysts expect that Colgate-Palmolive will post 3.75 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on CL shares. Stifel Nicolaus reduced their price target on shares of Colgate-Palmolive from $95.00 to $93.00 and set a “hold” rating for the company in a report on Monday, February 3rd. UBS Group lowered their target price on Colgate-Palmolive from $104.00 to $100.00 and set a “buy” rating for the company in a report on Monday, February 3rd. TD Cowen cut their price target on Colgate-Palmolive from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Barclays decreased their price objective on Colgate-Palmolive from $96.00 to $83.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Finally, Piper Sandler reduced their price target on Colgate-Palmolive from $121.00 to $112.00 and set an “overweight” rating for the company in a research report on Monday, January 6th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $101.61.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.